« Return to News | CROs/Service Providers

UBC Secures additional $150 million

Wednesday, July 7, 2010 03:00 PM

United BioSource Corporation (UBC), a global scientific and medical affairs organization based in Bethesda, Md., has secured a new line of credit that provides the company with up to $150 million in additional financing for acquisitions and other significant growth investments. Wells Fargo, PNC Bank, Capital One and JPMorgan Chase participated in financing the new credit facility.

“At a time when financial institutions are more cautious and lending standards are increasingly stringent, we are extremely pleased that the capital markets have provided such a strong vote of confidence for UBC,” said CEO Ethan Leder. “This capital will allow us to aggressively pursue our internal investments and targeted acquisition strategy.”

UBC was formed in 2003 with $153 million in private equity investments.  In 2009 the company secured an additional $125 million investment from Boston-based Berkshire Partners.  UBC recently opened its 10th office in Europe and its first in Japan.  The company employs over 1,400 in 21 countries, partnering with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care products.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.